```json
{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "parkin",
        "Protein_Change": {
          "ref": "A",
          "alt": "E",
          "position": "82"
        },
        "variant_string_id": "parkin A82E"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in the parkin gene, which encodes a ubiquitin ligase, are currently recognized as the main contributor to familial forms of Parkinson's disease (PD). A simple assumption about the effects of PD-linked mutations in parkin is that they impair or ablate the enzyme activity.",
          "judgment": "Yes",
          "reasoning": "The paper defines the disease mechanism as being related to impaired or ablated ubiquitin ligase activity of parkin, leading to familial PD."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study assesses solubility and intracellular localization of parkin, which can influence its function as a ubiquitin ligase.",
          "judgment": "Yes",
          "reasoning": "Assessing protein solubility and localization is relevant to the function of a ubiquitin ligase, as mislocalization or insolubility can impair its ability to interact with substrates and perform its enzymatic function. This is related to the disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "HEK 293 cells were transfected either with wild-type parkin or various parkin mutants (as indicated). ...The experiment was repeated 3 times with similar results.",
          "judgment": "Yes",
          "reasoning": "The study includes a wild-type control (normal/negative) and multiple replicates (3 times). The 'various parkin mutants' are the abnormal/positive controls.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study did not use known pathogenic or benign variants as controls, nor did they explicitly classify variants independently of PS3/BS3.",
          "judgment": "No",
          "reasoning": "The study only used wild-type parkin as a control. No other known pathogenic or benign variants of parkin were used.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study used a wild-type control but no other benign or pathogenic control variants were utilized.",
          "judgment": "N/A",
          "reasoning": "The study included a wild-type control, but did not include other known benign or pathogenic variants for control. Therefore, the count is less than 10",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The A82E variant does not show significant alteration in solubility or intracellular aggregation compared to wild-type, suggesting this variant does not significantly disrupt the function. Limited controls lead to PS3_supporting."
    },
    {
      "variant_id": {
        "Gene": "parkin",
        "Protein_Change": {
          "ref": "K",
          "alt": "N",
          "position": "161"
        },
        "variant_string_id": "parkin K161N"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in the parkin gene, which encodes a ubiquitin ligase, are currently recognized as the main contributor to familial forms of Parkinson's disease (PD). A simple assumption about the effects of PD-linked mutations in parkin is that they impair or ablate the enzyme activity.",
          "judgment": "Yes",
          "reasoning": "The paper defines the disease mechanism as being related to impaired or ablated ubiquitin ligase activity of parkin, leading to familial PD."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study assesses solubility and intracellular localization of parkin, which can influence its function as a ubiquitin ligase.",
          "judgment": "Yes",
          "reasoning": "Assessing protein solubility and localization is relevant to the function of a ubiquitin ligase, as mislocalization or insolubility can impair its ability to interact with substrates and perform its enzymatic function. This is related to the disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "HEK 293 cells were transfected either with wild-type parkin or various parkin mutants (as indicated). ...The experiment was repeated 3 times with similar results.",
          "judgment": "Yes",
          "reasoning": "The study includes a wild-type control (normal/negative) and multiple replicates (3 times). The 'various parkin mutants' are the abnormal/positive controls.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study did not use known pathogenic or benign variants as controls, nor did they explicitly classify variants independently of PS3/BS3.",
          "judgment": "No",
          "reasoning": "The study only used wild-type parkin as a control. No other known pathogenic or benign variants of parkin were used.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study used a wild-type control but no other benign or pathogenic control variants were utilized.",
          "judgment": "N/A",
          "reasoning": "The study included a wild-type control, but did not include other known benign or pathogenic variants for control. Therefore, the count is less than 10",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The K161N variant shows a significant alteration in solubility, with a higher proportion found in the insoluble fraction compared to wild-type parkin. This suggests the variant disrupts normal folding or protein interactions. Limited controls lead to PS3_supporting."
    },
    {
      "variant_id": {
        "Gene": "parkin",
        "Protein_Change": {
          "ref": "M",
          "alt": "L",
          "position": "192"
        },
        "variant_string_id": "parkin M192L"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in the parkin gene, which encodes a ubiquitin ligase, are currently recognized as the main contributor to familial forms of Parkinson's disease (PD). A simple assumption about the effects of PD-linked mutations in parkin is that they impair or ablate the enzyme activity.",
          "judgment": "Yes",
          "reasoning": "The paper defines the disease mechanism as being related to impaired or ablated ubiquitin ligase activity of parkin, leading to familial PD."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study assesses solubility and intracellular localization of parkin, which can influence its function as a ubiquitin ligase.",
          "judgment": "Yes",
          "reasoning": "Assessing protein solubility and localization is relevant to the function of a ubiquitin ligase, as mislocalization or insolubility can impair its ability to interact with substrates and perform its enzymatic function. This is related to the disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "HEK 293 cells were transfected either with wild-type parkin or various parkin mutants (as indicated). ...The experiment was repeated 3 times with similar results.",
          "judgment": "Yes",
          "reasoning": "The study includes a wild-type control (normal/negative) and multiple replicates (3 times). The 'various parkin mutants' are the abnormal/positive controls.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study did not use known pathogenic or benign variants as controls, nor did they explicitly classify variants independently of PS3/BS3.",
          "judgment": "No",
          "reasoning": "The study only used wild-type parkin as a control. No other known pathogenic or benign variants of parkin were used.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study used a wild-type control but no other benign or pathogenic control variants were utilized.",
          "judgment": "N/A",
          "reasoning": "The study included a wild-type control, but did not include other known benign or pathogenic variants for control. Therefore, the count is less than 10",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The M192L variant does not show significant alteration in solubility or intracellular aggregation compared to wild-type, suggesting this variant does not significantly disrupt the function. Limited controls lead to PS3_supporting."
    },
    {
      "variant_id": {
        "Gene": "parkin",
        "Protein_Change": {
          "ref": "K",
          "alt": "N",
          "position": "211"
        },
        "variant_string_id": "parkin K211N"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in the parkin gene, which encodes a ubiquitin ligase, are currently recognized as the main contributor to familial forms of Parkinson's disease (PD). A simple assumption about the effects of PD-linked mutations in parkin is that they impair or ablate the enzyme activity.",
          "judgment": "Yes",
          "reasoning": "The paper defines the disease mechanism as being related to impaired or ablated ubiquitin ligase activity of parkin, leading to familial PD."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study assesses solubility and intracellular localization of parkin, which can influence its function as a ubiquitin ligase.",
          "judgment": "Yes",
          "reasoning": "Assessing protein solubility and localization is relevant to the function of a ubiquitin ligase, as mislocalization or insolubility can impair its ability to interact with substrates and perform its enzymatic function. This is related to the disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "HEK 293 cells were transfected either with wild-type parkin or various parkin mutants (as indicated). ...The experiment was repeated 3 times with similar results.",
          "judgment": "Yes",
          "reasoning": "The study includes a wild-type control (normal/negative) and multiple replicates (3 times). The 'various parkin mutants' are the abnormal/positive controls.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study did not use known pathogenic or benign variants as controls, nor did they explicitly classify variants independently of PS3/BS3.",
          "judgment": "No",
          "reasoning": "The study only used wild-type parkin as a control. No other known pathogenic or benign variants of parkin were used.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study used a wild-type control but no other benign or pathogenic control variants were utilized.",
          "judgment": "N/A",
          "reasoning": "The study included a wild-type control, but did not include other known benign or pathogenic variants for control. Therefore, the count is less than 10",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The K211N variant does not show significant alteration in solubility or intracellular aggregation compared to wild-type, suggesting this variant does not significantly disrupt the function. Limited controls lead to PS3_supporting."
    },
    {
      "variant_id": {
        "Gene": "parkin",
        "Protein_Change": {
          "ref": "C",
          "alt": "Y",
          "position": "212"
        },
        "variant_string_id": "parkin C212Y"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in the parkin gene, which encodes a ubiquitin ligase, are currently recognized as the main contributor to familial forms of Parkinson's disease (PD). A simple assumption about the effects of PD-linked mutations in parkin is that they impair or ablate the enzyme activity.",
          "judgment": "Yes",
          "reasoning": "The paper defines the disease mechanism as being related to impaired or ablated ubiquitin ligase activity of parkin, leading to familial PD."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study assesses solubility and intracellular localization of parkin, which can influence its function as a ubiquitin ligase.",
          "judgment": "Yes",
          "reasoning": "Assessing protein solubility and localization is relevant to the function of a ubiquitin ligase, as mislocalization or insolubility can impair its ability to interact with substrates and perform its enzymatic function. This is related to the disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "HEK 293 cells were transfected either with wild-type parkin or various parkin mutants (as indicated). ...The experiment was repeated 3 times with similar results.",
          "judgment": "Yes",
          "reasoning": "The study includes a wild-type control (normal/negative) and multiple replicates (3 times). The 'various parkin mutants' are the abnormal/positive controls.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study did not use known pathogenic or benign variants as controls, nor did they explicitly classify variants independently of PS3/BS3.",
          "judgment": "No",
          "reasoning": "The study only used wild-type parkin as a control. No other known pathogenic or benign variants of parkin were used.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study used a wild-type control but no other benign or pathogenic control variants were utilized.",
          "judgment": "N/A",
          "reasoning": "The study included a wild-type control, but did not include other known benign or pathogenic variants for control. Therefore, the count is less than 10",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The C212Y variant shows a significant alteration in solubility, with a higher proportion found in the insoluble fraction compared to wild-type parkin, as well as increased aggregate formation. This suggests the variant disrupts normal folding or protein interactions. Limited controls lead to PS3_supporting."
    },
    {
      "variant_id": {
        "Gene": "parkin",
        "Protein_Change": {
          "ref": "T",
          "alt": "R",
          "position": "240"
        },
        "variant_string_id": "parkin T240R"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in the parkin gene, which encodes a ubiquitin ligase, are currently recognized as the main contributor to familial forms of Parkinson's disease (PD). A simple assumption about the effects of PD-linked mutations in parkin is that they impair or ablate the enzyme activity.",
          "judgment": "Yes",
          "reasoning": "The paper defines the disease mechanism as being related to impaired or ablated ubiquitin ligase activity of parkin, leading to familial PD."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study assesses solubility and intracellular localization of parkin, which can influence its function as a ubiquitin ligase.",
          "judgment": "Yes",
          "reasoning": "Assessing protein solubility and localization is relevant to the function of a ubiquitin ligase, as mislocalization or insolubility can impair its ability to interact with substrates and perform its enzymatic function. This is related to the disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "HEK 293 cells were transfected either with wild-type parkin or various parkin mutants (as indicated). ...The experiment was repeated 3 times with similar results.",
          "judgment": "Yes",
          "reasoning": "The study includes a wild-type control (normal/negative) and multiple replicates (3 times). The 'various parkin mutants' are the abnormal/positive controls.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study did not use known pathogenic or benign variants as controls, nor did they explicitly classify variants independently of PS3/BS3.",
          "judgment": "No",
          "reasoning": "The study only used wild-type parkin as a control. No other known pathogenic or benign variants of parkin were used.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study used a wild-type control but no other benign or pathogenic control variants were utilized.",
          "judgment": "N/A",
          "reasoning": "The study included a wild-type control, but did not include other known benign or pathogenic variants for control. Therefore, the count is less than 10",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The T240R variant does not show significant alteration in solubility or intracellular aggregation compared to wild-type, suggesting this variant does not significantly disrupt the function. Limited controls lead to PS3_supporting."
    },
    {
      "variant_id": {
        "Gene": "parkin",
        "Protein_Change": {
          "ref": "R",
          "alt": "C",
          "position": "256"
        },
        "variant_string_id": "parkin R256C"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in the parkin gene, which encodes a ubiquitin ligase, are currently recognized as the main contributor to familial forms of Parkinson's disease (PD). A simple assumption about the effects of PD-linked mutations in parkin is that they impair or ablate the enzyme activity.",
          "judgment": "Yes",
          "reasoning": "The paper defines the disease mechanism as being related to impaired or ablated ubiquitin ligase activity of parkin, leading to familial PD."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study assesses solubility and intracellular localization of parkin, which can influence its function as a ubiquitin ligase.",
          "judgment": "Yes",
          "reasoning": "Assessing protein solubility and localization is relevant to the function of a ubiquitin ligase, as mislocalization or insolubility can impair its ability to interact with substrates and perform its enzymatic function. This is related to the disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "HEK 293 cells were transfected either with wild-type parkin or various parkin mutants (as indicated). ...The experiment was repeated 3 times with similar results.",
          "judgment": "Yes",
          "reasoning": "The study includes a wild-type control (normal/negative) and multiple replicates (3 times). The 'various parkin mutants' are the abnormal/positive controls.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study did not use known pathogenic or benign variants as controls, nor did they explicitly classify variants independently of PS3/BS3.",
          "judgment": "No",
          "reasoning": "The study only used wild-type parkin as a control. No other known pathogenic or benign variants of parkin were used.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study used a wild-type control but no other benign or pathogenic control variants were utilized.",
          "judgment": "N/A",
          "reasoning": "The study included a wild-type control, but did not include other known benign or pathogenic variants for control. Therefore, the count is less than 10",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The R256C variant shows a significant alteration in solubility, with a higher proportion found in the insoluble fraction compared to wild-type parkin, as well as increased aggregate formation. This suggests the variant disrupts normal folding or protein interactions. Limited controls lead to PS3_supporting."
    },
    {
      "variant_id": {
        "Gene": "parkin",
        "Protein_Change": {
          "ref": "C",
          "alt": "X",
          "position": "268"
        },
        "variant_string_id": "parkin C268X"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in the parkin gene, which encodes a ubiquitin ligase, are currently recognized as the main contributor to familial forms of Parkinson's disease (PD). A simple assumption about the effects of PD-linked mutations in parkin is that they impair or ablate the enzyme activity.",
          "judgment": "Yes",
          "reasoning": "The paper defines the disease mechanism as being related to impaired or ablated ubiquitin ligase activity of parkin, leading to familial PD."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study assesses solubility and intracellular localization of parkin, which can influence its function as a ubiquitin ligase.",
          "judgment": "Yes",
          "reasoning": "Assessing protein solubility and localization is relevant to the function of a ubiquitin ligase, as mislocalization or insolubility can impair its ability to interact with substrates and perform its enzymatic function. This is related to the disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "HEK 293 cells were transfected either with wild-type parkin or various parkin mutants (as indicated). ...The experiment was repeated 3 times with similar results.",
          "judgment": "Yes",
          "reasoning": "The study includes a wild-type control (normal/negative) and multiple replicates (3 times). The 'various parkin mutants' are the abnormal/positive controls.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study did not use known pathogenic or benign variants as controls, nor did they explicitly classify variants independently of PS3/BS3.",
          "judgment": "No",
          "reasoning": "The study only used wild-type parkin as a control. No other known pathogenic or benign variants of parkin were used.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study used a wild-type control but no other benign or pathogenic control variants were utilized.",
          "judgment": "N/A",
          "reasoning": "The study included a wild-type control, but did not include other known benign or pathogenic variants for control. Therefore, the count is less than 10",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The C268X variant shows a significant alteration in solubility, with a higher proportion found in the insoluble fraction compared to wild-type parkin, as well as increased aggregate formation. This suggests the variant disrupts normal folding or protein interactions. Limited controls lead to PS3_supporting."
    },
    {
      "variant_id": {
        "Gene": "parkin",
        "Protein_Change": {
          "ref": "R",
          "alt": "W",
          "position": "275"
        },
        "variant_string_id": "parkin R275W"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in the parkin gene, which encodes a ubiquitin ligase, are currently recognized as the main contributor to familial forms of Parkinson's disease (PD). A simple assumption about the effects of PD-linked mutations in parkin is that they impair or ablate the enzyme activity.",
          "judgment": "Yes",
          "reasoning": "The paper defines the disease mechanism as being related to impaired or ablated ubiquitin ligase activity of parkin, leading to familial PD."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study assesses solubility and intracellular localization of parkin, which can influence its function as a ubiquitin ligase.",
          "judgment": "Yes",
          "reasoning": "Assessing protein solubility and localization is relevant to the function of a ubiquitin ligase, as mislocalization or insolubility can impair its ability to interact with substrates and perform its enzymatic function. This is related to the disease mechanism.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "HEK 293 cells were transfected either with wild-type parkin or various parkin mutants (as indicated). ...The experiment was repeated 3 times with similar results.",
          "judgment": "Yes",
          "reasoning": "The study includes a wild-type control (normal/negative) and multiple replicates (3 times). The 'various parkin mutants' are the abnormal/positive controls.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "The study did not use known pathogenic or benign variants as controls, nor did they explicitly classify variants independently of PS3/BS3.",
          "judgment": "No",
          "reasoning": "The study only used wild-type parkin as a control. No other known pathogenic or benign variants of parkin were used.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The study used a wild-type control but no other benign or pathogenic control variants were utilized.",
          "judgment": "N/A",
          "reasoning": "The study included a wild-type control, but did not include other known benign or pathogenic variants for control. Therefore, the count is less than 10",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The R275W variant shows a significant alteration in solubility, with a higher proportion found in the insoluble fraction compared to wild-type parkin, as well as increased aggregate formation. This suggests the variant disrupts normal folding or protein interactions. Limited controls lead to PS3_supporting."
    },
    {
      "variant_id": {
        "Gene": "parkin",
        "Protein_Change": {
          "ref": "D",
          "alt": "N",
          "position": "280"
        },
        "variant_string_id": "parkin D280N"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in the parkin gene, which encodes a ubiquitin ligase, are currently recognized as the main contributor to familial forms of Parkinson's disease (PD). A simple assumption about the effects of PD-linked mutations in parkin is that they impair or ablate the enzyme activity.",
          "judgment": "Yes",
          "reasoning": "The paper defines the disease mechanism as being related to impaired or ablated ubiquitin ligase activity of parkin, leading to familial PD."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study assesses solubility and intracellular localization of park